Exportar registro bibliográfico


Metrics:

Haploidentical bone marrow transplantation with post transplant cyclophosphamide for patients with X-linked adrenoleukodystrophy: a suitable choice in an urgent situation (2018)

  • Authors:
  • USP affiliated author: KOK, FERNANDO - FM
  • School: FM
  • DOI: 10.1038/s41409-017-0015-2
  • Subjects: TRANSPLANTE AUTÓLOGO; FÁRMACOS IMUNOSSUPRESSORES; REJEIÇÃO DE ENXERTO
  • Language: Inglês
  • Imprenta:
  • Source:
  • Online source accessDOI
    Informações sobre o DOI: 10.1038/s41409-017-0015-2 (Fonte: oaDOI API)
    • Este periódico é de assinatura
    • Este artigo é de acesso aberto
    • URL de acesso aberto
    • Cor do Acesso Aberto: bronze

    How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      FERNANDES, Juliana Folloni; KOK, Fernando. Haploidentical bone marrow transplantation with post transplant cyclophosphamide for patients with X-linked adrenoleukodystrophy: a suitable choice in an urgent situation. Bone marrow transplantation, London, v. 53, n. 4, p. 392-399, 2018. Disponível em: < http://dx.doi.org/10.1038/s41409-017-0015-2 > DOI: 10.1038/s41409-017-0015-2.
    • APA

      Fernandes, J. F., & Kok, F. (2018). Haploidentical bone marrow transplantation with post transplant cyclophosphamide for patients with X-linked adrenoleukodystrophy: a suitable choice in an urgent situation. Bone marrow transplantation, 53( 4), 392-399. doi:10.1038/s41409-017-0015-2
    • NLM

      Fernandes JF, Kok F. Haploidentical bone marrow transplantation with post transplant cyclophosphamide for patients with X-linked adrenoleukodystrophy: a suitable choice in an urgent situation [Internet]. Bone marrow transplantation. 2018 ; 53( 4): 392-399.Available from: http://dx.doi.org/10.1038/s41409-017-0015-2
    • Vancouver

      Fernandes JF, Kok F. Haploidentical bone marrow transplantation with post transplant cyclophosphamide for patients with X-linked adrenoleukodystrophy: a suitable choice in an urgent situation [Internet]. Bone marrow transplantation. 2018 ; 53( 4): 392-399.Available from: http://dx.doi.org/10.1038/s41409-017-0015-2

    Referências citadas na obra
    Moser HW. Komrower Lecture. Adrenoleukodystrophy: natural history, treatment and outcome. J Inherit Metab Dis. 1995;18:435–47.
    Pereira Fdos S, Matte U, Habekost CT, de Castilhos RM, El Husny AS, Lourenço CM, et al. Mutations, clinical findings and survival estimates in South American patients with X-linked adrenoleukodystrophy. PLoS ONE. 2012;7:e34195.
    Moser HW, Raymond GV, Dubey P. Adrenoleukodystrophy: new approaches to a neurodegenerative disease. JAMA. 2005;294:3131–4.
    Engelen M, Kemp S, Poll-The BT. X-linked adrenoleukodystrophy: pathogenesis and treatment. Curr Neurol Neurosci Rep. 2014;14:486.
    Moser HW. Therapy of X-linked adrenoleukodystrophy. NeuroRx. 2006;3:246–53.5.
    Mahmood A, Raymond GV, Dubey P, Peters C, Moser H. Survival analysis of haematopoietic cell transplantation for childhood cerebral X-linked adrenoleukodystrophy: a comparison study. Lancet Neurol. 2007;6:687–92.
    Peters C, Charnas LR, Tan Y, Ziegler RS, Shapiro EG, DeFor T, et al. Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999. Blood. 2004;104:881–8.
    Moser HW. Adrenoleukodystrophy: phenotype, genetics, pathogenesis and therapy. Brain. 1997;120(Part 8):1485–508.
    Loes DJ, Hite S, Moser H, Stillman AE, Shapiro E, Lockman L, et al. Adrenoleukodystrophy: a scoring method for brain MR observations. Am J Neuroradiol. 1994;15:1761–6.
    Miller WP, Rothman SM, Nascene D, Kivisto T, DeFor TE, Ziegler RS, et al. Outcomes after allogeneic hematopoietic cell transplantation for childhood cerebral adrenoleukodystrophy: the largest single-institution cohort report. Blood. 2011;118:1971–8.
    Shapiro E, Krivit W, Lockman L, Jambaqué I, Peters C, Cowan M, et al. Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy. Lancet. 2000;356:713–8.
    Okamura K, Watanabe T, Onishi T, Watanabe H, Fujii E, Mori K, et al. Successful allogeneic unrelated bone marrow transplantation using reduced-intensity conditioning for the treatment of X-linked adrenoleukodystrophy in a one-yr-old boy. Pediatr Transplant. 2009;13:130–3.
    Beam D, Poe MD, Provenzale JM, Szabolcs P, Martin PL, Prasad V, et al. Outcomes of unrelated umbilical cord blood transplantation for X-linked adrenoleukodystrophy. Biol Blood Marrow Transplant. 2007;13:665–74.
    Jiang H, Jiang MY, Liu S, Cai YN, Liang CL, Liu L. Combination of a haploidentical stem cell transplant with umbilical cord blood for cerebral X-linked adrenoleukodystrophy. Pediatr Neurol. 2015;53:1635.e1.
    Luznik L, Jalla S, Engstrom LW, Iannone R, Fuchs EJ. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001;98:3456–64.
    Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14:641–50.
    Luznik L, O’Donnell PV, Fuchs EJ. Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol. 2012;39:683–93.
    Brodsky RA, Luznik L, Bolaños-Meade J, Leffell MS, Jones RJ, Fuchs EJ. Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases. Bone Marrow Transplant. 2008;42:523–7.
    Bolaños-Meade J, Fuchs EJ, Luznik L, Lanzkron SM, Gamper CJ, Jones RJ, et al. HLA-haploidentical bone marrow transplantation with post transplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood. 2012;120:4285–91.
    Klein OR, Chen AR, Gamper C, Loeb D, Zambidis E, Llosa N, et al. Alternative-donor hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for nonmalignant disorders. Biol Blood Marrow Transplant. 2016;22:895–901.
    Esteves I, Bonfim C, Pasquini R, Funke V, Pereira NF, Rocha V, et al. Haploidentical BMT and post-transplant Cy for severe aplastic anemia: a multicenter retrospective study. Bone Marrow Transplant. 2015;50:685–9.
    Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-vs.-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295–304.
    Storb R, Prentice RL, Sullivan KM, Shulman HM, Deeg HJ, Doney KC, et al. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med. 1983;98:461–6.
    Wechsler D. Wechsler intelligence scale for children. 3rd ed (WISC-III). San Antonio: The Psychological Corporation; 1991.
    Wechsler D. Wechsler adult intelligence scale. 3rd ed (WAIS-III). San Antonio: The Psychological Corporation; 1997.
    Moser HW, Raymond GV, Koehler W, Sokolowski P, Hanefeld F, Korenke GC, et al. Evaluation of the preventive effect of glyceryl trioleate-trierucate (“Lorenzo’s oil”) therapy in X-linked adrenoleukodystrophy: results of two concurrent trials. Adv Exp Med Biol. 2003;544:369–87.
    Moser HW, Mahmood A. New insights about hematopoietic stem cell transplantation in adrenoleukodystrophy. Arch Neurol. 2007;64:631–2.
    Krivit W, Sung JH, Shapiro EG, Lockman LA. Microglia: the effector cell for reconstitution of the central nervous system following bone marrow transplantation for lysosomal and peroxisomal storage diseases. Cell Transplant. 1995;4:385–92.
    Wilkinson FL, Sergijenko A, Langford-Smith K, et al. Busulfan conditioning enhances engraftment of hematopoietic donor-derived cells in the brain compared with irradiation. Mol Ther. 2013;21:868–76.
    O’Donnell P, Raj K, Pagliuca A. High fever occurring 4 to 5 days post-transplant of haploidentical bone marrow or peripheral blood stem cells after reduced-intensity conditioning associated with the use of post-transplant cyclophosphamide as prophylaxis for graft-versus-host disease. Biol Blood Marrow Transplant. 2015;21:197–8.

Digital Library of Intellectual Production of Universidade de São Paulo     2012 - 2020